Added to YB: 2026-04-07
Pitch date: 2026-04-03
NVAX [bullish]
Novavax, Inc.
+2.44%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
Market Cap
$1.3B
Pitch Price
$7.78
Price Target
22.00 (+176%)
Dividend
N/A
EV/EBITDA
1.33
P/E
2.99
EV/Sales
0.71
Sector
Biotechnology
Category
growth
DD: Novovax ($NVAX)
NVAX: Protein vaccine maker pivoted to asset-light IP licensing model. Sanofi deal offloads commercial/manufacturing risk w/ $1.2B milestones + double-digit royalties. Lead asset: COVID-flu combo (CIC) vaccine, Phase 3 readout late 2026. Pfizer Matrix-M deal ($30M upfront, $500M milestones) validates adjuvant platform. $751M cash, $440M net income in 2025, 53% SG&A cut. rNPV model: 65% PoS, 12.5% WACC, $22 PT (+186%). Bull: CIC captures 15% of $7B flu market by 2030. Bear: CIC fails Phase 3, vaccine uptake declines.
Read full article (8 min)